The preferred treatment for patent ductus arteriosus (PDA) in neonates is indomethacin or ibuprofen, administered after birth. While PDA is more common in premature infants, a family history of heart defects can increase the risk. Diagnosis typically occurs during postnatal baby checks, often due to the presence of a murmur or symptoms of heart failure. Doing nothing is not a recommended approach, as spontaneous closure is rare. Surgery may be necessary if medical management is unsuccessful. Prostaglandin E1 is not the best answer, as it is typically used in cases where PDA is associated with another congenital heart defect. Indomethacin or ibuprofen are not given to the mother during the antenatal period.

Understanding Patent Ductus Arteriosus

Patent ductus arteriosus is a type of congenital heart defect that is generally classified as ‘acyanotic’. However, if left uncorrected, it can eventually result in late cyanosis in the lower extremities, which is termed differential cyanosis. This condition is caused by a connection between the pulmonary trunk and descending aorta. Normally, the ductus arteriosus closes with the first breaths due to increased pulmonary flow, which enhances prostaglandins clearance. However, in some cases, this connection remains open, leading to patent ductus arteriosus.

This condition is more common in premature babies, those born at high altitude, or those whose mothers had rubella infection in the first trimester. The features of patent ductus arteriosus include a left subclavicular thrill, continuous ‘machinery’ murmur, large volume, bounding, collapsing pulse, wide pulse pressure, and heaving apex beat.

The management of patent ductus arteriosus involves the use of indomethacin or ibuprofen, which are given to the neonate. These medications inhibit prostaglandin synthesis and close the connection in the majority of cases. If patent ductus arteriosus is associated with another congenital heart defect amenable to surgery, then prostaglandin E1 is useful to keep the duct open until after surgical repair. Understanding patent ductus arteriosus is important for early diagnosis and management of this condition.

The Purkinje fibres have the highest conduction velocities in the heart’s electrical conduction system. The process starts with the SA node generating spontaneous action potentials, which are then conducted across both atria through cell to cell conduction at a speed of approximately 1 m/s. The only pathway for the action potential to enter the ventricles is through the AV node, which has a slow conduction speed of 0.05ms to allow for complete atrial contraction and ventricular filling. The action potentials are then conducted through the Bundle of His, which splits into the left and right bundle branches, with a conduction speed of approximately 2m/s. Finally, the action potential reaches the Purkinje fibres, which are specialized conducting cells that allow for a faster conduction speed of 2-4m/s. This fast conduction speed is crucial for a synchronized and efficient contraction of the ventricle, generating pressure during systole.

Understanding the Cardiac Action Potential and Conduction Velocity

The cardiac action potential is a series of electrical events that occur in the heart during each heartbeat. It is responsible for the contraction of the heart muscle and the pumping of blood throughout the body. The action potential is divided into five phases, each with a specific mechanism. The first phase is rapid depolarization, which is caused by the influx of sodium ions. The second phase is early repolarization, which is caused by the efflux of potassium ions. The third phase is the plateau phase, which is caused by the slow influx of calcium ions. The fourth phase is final repolarization, which is caused by the efflux of potassium ions. The final phase is the restoration of ionic concentrations, which is achieved by the Na+/K+ ATPase pump.

Conduction velocity is the speed at which the electrical signal travels through the heart. The speed varies depending on the location of the signal. Atrial conduction spreads along ordinary atrial myocardial fibers at a speed of 1 m/sec. AV node conduction is much slower, at 0.05 m/sec. Ventricular conduction is the fastest in the heart, achieved by the large diameter of the Purkinje fibers, which can achieve velocities of 2-4 m/sec. This allows for a rapid and coordinated contraction of the ventricles, which is essential for the proper functioning of the heart. Understanding the cardiac action potential and conduction velocity is crucial for diagnosing and treating heart conditions.

The primary goal of statins is to lower cholesterol levels in the bloodstream, which in turn reduces the risk of cardiovascular events. This is achieved by inhibiting HMG-CoA reductase in the liver, which prevents the synthesis of mevalonate, a precursor to LDLs. As a result, statins decrease the amount of cholesterol being transported to body tissues by LDLs. However, statins do not affect the levels of HDLs, which transport cholesterol from body tissues back to the liver.

Statins are drugs that inhibit the action of HMG-CoA reductase, which is the enzyme responsible for cholesterol synthesis in the liver. However, they can cause adverse effects such as myopathy, liver impairment, and an increased risk of intracerebral hemorrhage in patients with a history of stroke. Statins should not be taken during pregnancy or in combination with macrolides. NICE recommends statins for patients with established cardiovascular disease, a 10-year cardiovascular risk of 10% or higher, type 2 diabetes mellitus, or type 1 diabetes mellitus with certain criteria. It is recommended to take statins at night, especially simvastatin, which has a shorter half-life than other statins. NICE recommends atorvastatin 20mg for primary prevention and atorvastatin 80 mg for secondary prevention.

Orthopnoea is a useful indicator to distinguish between heart failure and COPD.

The Framingham diagnostic criteria for heart failure include major criteria such as acute pulmonary oedema and cardiomegaly, as well as minor criteria like ankle oedema and dyspnoea on exertion. Other minor criteria include hepatomegaly, nocturnal cough, pleural effusion, tachycardia (>120 /min), neck vein distension, and a third heart sound.

In this case, the patient exhibits orthopnoea (needing an extra pillow to alleviate breathlessness), rales (crackles heard during inhalation), and dyspnoea on exertion, all of which are indicative of heart failure.

While COPD can present with similar symptoms such as coughing, fatigue, shortness of breath, and desaturation, the presence of orthopnoea helps to differentiate between the two conditions.

Pulmonary fibrosis, on the other hand, does not typically present with orthopnoea.

Features of Chronic Heart Failure

Chronic heart failure is a condition that affects the heart’s ability to pump blood effectively. It is characterized by several features that can help in its diagnosis. Dyspnoea, or shortness of breath, is a common symptom of chronic heart failure. Patients may also experience coughing, which can be worse at night and accompanied by pink or frothy sputum. Orthopnoea, or difficulty breathing while lying down, and paroxysmal nocturnal dyspnoea, or sudden shortness of breath at night, are also common symptoms.

Another feature of chronic heart failure is the presence of a wheeze, known as a cardiac wheeze. Patients may also experience weight loss, known as cardiac cachexia, which occurs in up to 15% of patients. However, this may be hidden by weight gained due to oedema. On examination, bibasal crackles may be heard, and signs of right-sided heart failure, such as a raised JVP, ankle oedema, and hepatomegaly, may be present.

In summary, chronic heart failure is a condition that can be identified by several features, including dyspnoea, coughing, orthopnoea, paroxysmal nocturnal dyspnoea, wheezing, weight loss, bibasal crackles, and signs of right-sided heart failure. Early recognition and management of these symptoms can help improve outcomes for patients with chronic heart failure.

Furosemide is a medication that is often prescribed to patients with heart failure who have excess fluid in their bodies. It works by inhibiting the Na-K-Cl cotransporter in the thick ascending limb of the loop of Henle, which prevents the reabsorption of sodium. This results in a less hypertonic renal medulla and reduces the osmotic force that causes water to be reabsorbed from the collecting ducts. As a result, more water is excreted through the kidneys.

It is important to be aware of the common side effects of loop diuretics, which are listed in the notes below.

Loop Diuretics: Mechanism of Action and Clinical Applications

Loop diuretics, such as furosemide and bumetanide, are medications that inhibit the Na-K-Cl cotransporter (NKCC) in the thick ascending limb of the loop of Henle. By doing so, they reduce the absorption of NaCl, resulting in increased urine output. Loop diuretics act on NKCC2, which is more prevalent in the kidneys. These medications work on the apical membrane and must first be filtered into the tubules by the glomerulus before they can have an effect. Patients with poor renal function may require higher doses to ensure sufficient concentration in the tubules.

Loop diuretics are commonly used in the treatment of heart failure, both acutely (usually intravenously) and chronically (usually orally). They are also indicated for resistant hypertension, particularly in patients with renal impairment. However, loop diuretics can cause adverse effects such as hypotension, hyponatremia, hypokalemia, hypomagnesemia, hypochloremic alkalosis, ototoxicity, hypocalcemia, renal impairment, hyperglycemia (less common than with thiazides), and gout. Therefore, careful monitoring of electrolyte levels and renal function is necessary when using loop diuretics.

Glycoprotein IIb/IIIa Receptor Antagonists

Glycoprotein IIb/IIIa receptor antagonists are a class of drugs that inhibit the function of the glycoprotein IIb/IIIa receptor, which is found on the surface of platelets. These drugs are used to prevent blood clots from forming in patients with acute coronary syndrome, unstable angina, or during percutaneous coronary intervention (PCI).

Examples of glycoprotein IIb/IIIa receptor antagonists include abciximab, eptifibatide, and tirofiban. These drugs work by blocking the binding of fibrinogen to the glycoprotein IIb/IIIa receptor, which prevents platelet aggregation and the formation of blood clots.

Glycoprotein IIb/IIIa receptor antagonists are typically administered intravenously and are used in combination with other antiplatelet agents, such as aspirin and clopidogrel. While these drugs are effective at preventing blood clots, they can also increase the risk of bleeding. Therefore, careful monitoring of patients is necessary to ensure that the benefits of these drugs outweigh the risks.

An anterior MI is the most probable diagnosis, given the absence of ST changes in the inferior leads. Aortic dissection is therefore less probable.

The following table displays the relationship between ECG changes and the affected coronary artery territories. Anteroseptal changes in V1-V4 indicate involvement of the left anterior descending artery, while inferior changes in II, III, and aVF suggest the right coronary artery is affected. Anterolateral changes in V4-6, I, and aVL may indicate involvement of either the left anterior descending or left circumflex artery, while lateral changes in I, aVL, and possibly V5-6 suggest the left circumflex artery is affected. Posterior changes in V1-3 may indicate a posterior infarction, which is typically caused by the left circumflex artery but can also be caused by the right coronary artery. Reciprocal changes of STEMI are often seen as horizontal ST depression, tall R waves, upright T waves, and a dominant R wave in V2. Posterior infarction is confirmed by ST elevation and Q waves in posterior leads (V7-9), usually caused by the left circumflex artery but also possibly the right coronary artery. It is important to note that a new LBBB may indicate acute coronary syndrome.

Diagram showing the correlation between ECG changes and coronary territories in acute coronary syndrome.

Hypokalaemia can be identified through a prolonged PR interval on an ECG. However, this same ECG sign may also be present in cases of hyperkalaemia. Additional ECG signs of hypokalaemia include small or absent P waves, tall tented T waves, and broad bizarre QRS complexes. On the other hand, hyperkalaemia can be identified through ECG signs such as long PR intervals, a sine wave pattern, and tall tented T waves, as well as broad bizarre QRS complexes.

Hypokalaemia, a condition characterized by low levels of potassium in the blood, can be detected through ECG features. These include the presence of U waves, small or absent T waves (which may occasionally be inverted), a prolonged PR interval, ST depression, and a long QT interval. The ECG image provided shows typical U waves and a borderline PR interval. To remember these features, one user suggests the following rhyme: In Hypokalaemia, U have no Pot and no T, but a long PR and a long QT.

The Specificity, Negative Predictive Value, Sensitivity, and Positive Predictive Value of a Medical Test

Medical tests are designed to accurately identify the presence or absence of a particular condition. In evaluating the effectiveness of a medical test, several measures are used, including specificity, negative predictive value, sensitivity, and positive predictive value. Specificity refers to the number of individuals without the condition who are accurately identified as such by the test. On the other hand, sensitivity refers to the number of individuals with the condition who are correctly identified by the test.

The negative predictive value of a medical test refers to the proportion of true negatives who are correctly identified by the test. This means that the test accurately identifies individuals who do not have the condition. The positive predictive value, on the other hand, refers to the proportion of true positives who are correctly identified by the test. This means that the test accurately identifies individuals who have the condition.

In summary, the specificity, negative predictive value, sensitivity, and positive predictive value of a medical test is crucial in evaluating its effectiveness in accurately identifying the presence or absence of a particular condition. These measures help healthcare professionals make informed decisions about patient care and treatment.

Understanding Ventricular Septal Defect

Ventricular septal defect (VSD) is a common congenital heart disease that affects many individuals. It is caused by a hole in the wall that separates the two lower chambers of the heart. In some cases, VSDs may close on their own, but in other cases, they require specialized management.

There are various causes of VSDs, including chromosomal disorders such as Down’s syndrome, Edward’s syndrome, Patau syndrome, and cri-du-chat syndrome. Congenital infections and post-myocardial infarction can also lead to VSDs. The condition can be detected during routine scans in utero or may present post-natally with symptoms such as failure to thrive, heart failure, hepatomegaly, tachypnea, tachycardia, pallor, and a pansystolic murmur.

Management of VSDs depends on the size and symptoms of the defect. Small VSDs that are asymptomatic may require monitoring, while moderate to large VSDs may result in heart failure and require nutritional support, medication for heart failure, and surgical closure of the defect.

Complications of VSDs include aortic regurgitation, infective endocarditis, Eisenmenger’s complex, right heart failure, and pulmonary hypertension. Eisenmenger’s complex is a severe complication that results in cyanosis and clubbing and is an indication for a heart-lung transplant. Women with pulmonary hypertension are advised against pregnancy as it carries a high risk of mortality.

In conclusion, VSD is a common congenital heart disease that requires specialized management. Early detection and appropriate treatment can prevent severe complications and improve outcomes for affected individuals.

Patients with reduced ejection fraction heart failure (HF-rEF) usually experience systolic dysfunction, which refers to the impaired ability of the myocardium to contract during systole.

Types of Heart Failure

Heart failure is a clinical syndrome where the heart cannot pump enough blood to meet the body’s metabolic needs. It can be classified in multiple ways, including by ejection fraction, time, and left/right side. Patients with heart failure may have a normal or abnormal left ventricular ejection fraction (LVEF), which is measured using echocardiography. Reduced LVEF is typically defined as < 35 to 40% and is termed heart failure with reduced ejection fraction (HF-rEF), while preserved LVEF is termed heart failure with preserved ejection fraction (HF-pEF). Heart failure can also be described as acute or chronic, with acute heart failure referring to an acute exacerbation of chronic heart failure. Left-sided heart failure is more common and may be due to increased left ventricular afterload or preload, while right-sided heart failure is caused by increased right ventricular afterload or preload. High-output heart failure is another type of heart failure that occurs when a normal heart is unable to pump enough blood to meet the body's metabolic needs. By classifying heart failure in these ways, healthcare professionals can better understand the underlying causes and tailor treatment plans accordingly. It is important to note that many guidelines for the management of heart failure only cover HF-rEF patients and do not address the management of HF-pEF patients. Understanding the different types of heart failure can help healthcare professionals provide more effective care for their patients.

BNP is produced by the ventricles of the heart when the cardiomyocytes are excessively stretched. Its overall effect is to reduce blood pressure by decreasing systemic vascular resistance and increasing natriuresis.

Troponin is a protein that plays a role in cardiac muscle contraction and is a specific and sensitive marker for myocardial damage in cases of myocardial infarction.

Creatine kinase and LDH can be used as acute markers for myocardial infarction.

Myoglobin is released after muscle damage, but it is not specific to acute myocardial infarction and is typically measured in cases of rhabdomyolysis.

B-type natriuretic peptide (BNP) is a hormone that is primarily produced by the left ventricular myocardium in response to strain. Although heart failure is the most common cause of elevated BNP levels, any condition that causes left ventricular dysfunction, such as myocardial ischemia or valvular disease, may also raise levels. In patients with chronic kidney disease, reduced excretion may also lead to elevated BNP levels. Conversely, treatment with ACE inhibitors, angiotensin-2 receptor blockers, and diuretics can lower BNP levels.

BNP has several effects, including vasodilation, diuresis, natriuresis, and suppression of both sympathetic tone and the renin-angiotensin-aldosterone system. Clinically, BNP is useful in diagnosing patients with acute dyspnea. A low concentration of BNP (<100 pg/mL) makes a diagnosis of heart failure unlikely, but elevated levels should prompt further investigation to confirm the diagnosis. Currently, NICE recommends BNP as a helpful test to rule out a diagnosis of heart failure. In patients with chronic heart failure, initial evidence suggests that BNP is an extremely useful marker of prognosis and can guide treatment. However, BNP is not currently recommended for population screening for cardiac dysfunction.

The gold standard investigation for intracranial vascular disease is cerebral angiography, which can diagnose intracranial aneurysms and other vascular diseases by visualizing arteries and veins using contrast dye injected into the bloodstream. This technique can also create 3-D reconstructed images that allow for a comprehensive view of the cerebral vessels and accompanying pathology from all angles.

Individuals with PKD are at an increased risk of cerebral aneurysms, which can lead to subarachnoid hemorrhages.

Flow-Sensitive MRI (FS MRI) is a useful tool that combines functional MRI with images of cerebrospinal fluid (CSF) flow. It can aid in planning the surgical removal of skull base tumors, spinal cord tumors, or tumors causing hydrocephalus.

While contrast and non-contrast CT scans are commonly used as the first line of investigation for intracranial lesions, they are not the gold standard and are superseded by cerebral angiography.

Understanding Cerebral Blood Flow and Angiography

Cerebral blood flow is regulated by the central nervous system, which can adjust its own blood supply. Various factors can affect cerebral pressure, including CNS metabolism, trauma, pressure, and systemic carbon dioxide levels. The most potent mediator is PaCO2, while acidosis and hypoxemia can also increase cerebral blood flow to a lesser degree. In patients with head injuries, increased intracranial pressure can impair blood flow. The Monro-Kelly Doctrine governs intracerebral pressure, which considers the brain as a closed box, and changes in pressure are offset by the loss of cerebrospinal fluid. However, when this is no longer possible, intracranial pressure rises.

Cerebral angiography is an invasive test that involves injecting contrast media into the carotid artery using a catheter. Radiographs are taken as the dye works its way through the cerebral circulation. This test can be used to identify bleeding aneurysms, vasospasm, and arteriovenous malformations, as well as differentiate embolism from large artery thrombosis. Understanding cerebral blood flow and angiography is crucial in diagnosing and treating various neurological conditions.

If a patient with acute heart failure does not show improvement with appropriate medication, CPAP should be considered as a viable treatment option.

Heart failure requires acute management, with recommended treatments including IV loop diuretics such as furosemide or bumetanide. Oxygen may also be given in accordance with British Thoracic Society guidelines to maintain oxygen saturations between 94-98%. Vasodilators such as nitrates should not be routinely given to all patients, but may be considered for those with concomitant myocardial ischaemia, severe hypertension, or regurgitant aortic or mitral valve disease. However, hypotension is a major side-effect and contraindication.

For patients with respiratory failure, CPAP may be used. In cases of hypotension or cardiogenic shock, treatment can be challenging as loop diuretics and nitrates may exacerbate hypotension. Inotropic agents like dobutamine may be considered for patients with severe left ventricular dysfunction and potentially reversible cardiogenic shock. Vasopressor agents like norepinephrine are typically only used if there is insufficient response to inotropes and evidence of end-organ hypoperfusion. Mechanical circulatory assistance such as intra-aortic balloon counterpulsation or ventricular assist devices may also be used.

While opiates were previously used routinely to reduce dyspnoea/distress in patients, NICE now advises against routine use due to studies suggesting increased morbidity in patients given opiates. Regular medication for heart failure such as beta-blockers and ACE-inhibitors should be continued, with beta-blockers only stopped if the patient has a heart rate less than 50 beats per minute, second or third degree atrioventricular block, or shock.

Aschoff bodies, which are granulomatous nodules consisting of giant cells around areas of fibrinoid necrosis, are pathognomonic for rheumatic heart disease. This condition is often a sequela of acute rheumatic heart fever, which occurs due to molecular mimicry where antibodies to the bacteria causing a pharyngeal infection react with the cardiac myocyte antigen resulting in valve destruction. The bacterial organism responsible for the pharyngeal infection leading to rheumatic heart disease is the group A β-hemolytic Streptococcus pyogenes.

In contrast, Staphylococcus aureus is a gram-positive, coagulase-positive bacteria that often causes acute bacterial endocarditis with large vegetations on previously normal cardiac valves. Bacterial endocarditis typically presents with a fever and new-onset murmur, and may be associated with other signs such as Roth spots, Osler nodes, Janeway lesions, and splinter hemorrhages. Staphylococcus epidermidis, on the other hand, is a gram-positive, coagulase-negative bacteria that often causes bacterial endocarditis on prosthetic valves. Streptococcus viridans, a gram-positive, α-hemolytic bacteria, typically causes subacute bacterial endocarditis in individuals with a diseased or previously abnormal valve, with smaller vegetations compared to acute bacterial endocarditis.

Rheumatic fever is a condition that occurs as a result of an immune response to a recent Streptococcus pyogenes infection, typically occurring 2-4 weeks after the initial infection. The pathogenesis of rheumatic fever involves the activation of the innate immune system, leading to antigen presentation to T cells. B and T cells then produce IgG and IgM antibodies, and CD4+ T cells are activated. This immune response is thought to be cross-reactive, mediated by molecular mimicry, where antibodies against M protein cross-react with myosin and the smooth muscle of arteries. This response leads to the clinical features of rheumatic fever, including Aschoff bodies, which are granulomatous nodules found in rheumatic heart fever.

To diagnose rheumatic fever, evidence of recent streptococcal infection must be present, along with 2 major criteria or 1 major criterion and 2 minor criteria. Major criteria include erythema marginatum, Sydenham’s chorea, polyarthritis, carditis and valvulitis, and subcutaneous nodules. Minor criteria include raised ESR or CRP, pyrexia, arthralgia, and prolonged PR interval.

Management of rheumatic fever involves antibiotics, typically oral penicillin V, as well as anti-inflammatories such as NSAIDs as first-line treatment. Any complications that develop, such as heart failure, should also be treated. It is important to diagnose and treat rheumatic fever promptly to prevent long-term complications such as rheumatic heart disease.

The binding of troponin T to tropomyosin results in the formation of a troponin-tropomyosin complex. The clinical and electrographic characteristics suggest the presence of an inferior myocardial infarction, which is confirmed by the elevated levels of troponin. Troponin T is highly specific to myocardial damage. On the other hand, troponin C binds to calcium ions and is released by damage to both skeletal and cardiac muscle, making it an insensitive marker for myocardial necrosis. Troponin I binds to actin and helps to maintain the troponin-tropomyosin complex in place. It is also specific to myocardial damage. Myosin is the thick component of muscle fibers, and actin slides along myosin to generate muscle contraction. The sarcoplasmic reticulum plays a crucial role in regulating the concentration of calcium ions in the cytoplasm of striated muscle cells.

Understanding Troponin: The Proteins Involved in Muscle Contraction

Troponin is a group of three proteins that play a crucial role in the contraction of skeletal and cardiac muscles. These proteins work together to regulate the interaction between actin and myosin, which is essential for muscle contraction. The three subunits of troponin are troponin C, troponin T, and troponin I.

Troponin C is responsible for binding to calcium ions, which triggers the contraction of muscle fibers. Troponin T binds to tropomyosin, forming a complex that helps regulate the interaction between actin and myosin. Finally, troponin I binds to actin, holding the troponin-tropomyosin complex in place and preventing muscle contraction when it is not needed.

Understanding the role of troponin is essential for understanding how muscles work and how they can be affected by various diseases and conditions. By regulating the interaction between actin and myosin, troponin plays a critical role in muscle contraction and is a key target for drugs used to treat conditions such as heart failure and skeletal muscle disorders.

The inheritance pattern of HOCM is autosomal dominant, which means that it can be passed down from generation to generation. Symptoms of HOCM may include exertional dyspnoea, angina, syncope, and an ejection systolic murmur. It is important to note that there may be a family history of similar cardiac problems or sudden death due to ventricular arrhythmias. Autosomal recessive, mitochondrial inheritance, and X-linked dominant inheritance are not applicable to HOCM.

Hypertrophic obstructive cardiomyopathy (HOCM) is a genetic disorder that affects muscle tissue and is inherited in an autosomal dominant manner. It is caused by mutations in genes that encode contractile proteins, with the most common defects involving the β-myosin heavy chain protein or myosin-binding protein C. HOCM is characterized by left ventricle hypertrophy, which leads to decreased compliance and cardiac output, resulting in predominantly diastolic dysfunction. Biopsy findings show myofibrillar hypertrophy with disorganized myocytes and fibrosis. HOCM is often asymptomatic, but exertional dyspnea, angina, syncope, and sudden death can occur. Jerky pulse, systolic murmurs, and double apex beat are also common features. HOCM is associated with Friedreich’s ataxia and Wolff-Parkinson White. ECG findings include left ventricular hypertrophy, non-specific ST segment and T-wave abnormalities, and deep Q waves. Atrial fibrillation may occasionally be seen.

The correct answer is the atrioventricular (AV) node, which is located within the atrioventricular septum near the septal cusp of the tricuspid valve. It regulates the spread of excitation from the atria to the ventricles.

The sinoatrial (SA) node is situated in the right atrium, at the top of the crista terminalis where the right atrium meets the superior vena cava. It is where cardiac impulses originate in a healthy heart.

The bundle of His is a group of specialized cardiac myocytes that transmit the electrical impulse from the AV node to the ventricles.

The Purkinje fibers are a collection of fibers that distribute the cardiac impulse throughout the muscular ventricular walls.

The bundle of Kent is not present in a healthy heart. It refers to the accessory pathway between the atria and ventricles that exists in Wolff-Parkinson-White (WPW) syndrome. This additional conduction pathway allows for fast conduction of impulses between the atria and ventricles, without the additional control of the AV node. This results in a type of supraventricular tachycardia known as an atrioventricular re-entrant tachycardia.

The patient in the above question has presented with palpitations and shortness of breath. An irregularly irregular pulse is highly indicative of atrial fibrillation (AF). ECG signs of atrial fibrillation include an irregularly irregular rhythm and absent P waves. In AF, the impulses from the fibrillating heart are typically prevented from reaching the ventricles by the AV node.

The heart has four chambers and generates pressures of 0-25 mmHg on the right side and 0-120 mmHg on the left. The cardiac output is the product of heart rate and stroke volume, typically 5-6L per minute. The cardiac impulse is generated in the sino atrial node and conveyed to the ventricles via the atrioventricular node. Parasympathetic and sympathetic fibers project to the heart via the vagus and release acetylcholine and noradrenaline, respectively. The cardiac cycle includes mid diastole, late diastole, early systole, late systole, and early diastole. Preload is the end diastolic volume and afterload is the aortic pressure. Laplace’s law explains the rise in ventricular pressure during the ejection phase and why a dilated diseased heart will have impaired systolic function. Starling’s law states that an increase in end-diastolic volume will produce a larger stroke volume up to a point beyond which stroke volume will fall. Baroreceptor reflexes and atrial stretch receptors are involved in regulating cardiac output.

The ophthalmic artery is the first branch of the internal carotid artery and supplies the orbit. If the internal carotid artery is affected by disease, it can lead to vision loss. However, disease of the external carotid artery, which supplies structures of the face and neck, or its branches such as the facial artery (which supplies skin and muscles of the face), lingual artery (which supplies the tongue and oral mucosa), or middle meningeal artery (which supplies the cranial dura), would not result in vision loss. Disease of the middle meningeal artery is commonly associated with extradural hematoma.

The Circle of Willis is an anastomosis formed by the internal carotid arteries and vertebral arteries on the bottom surface of the brain. It is divided into two halves and is made up of various arteries, including the anterior communicating artery, anterior cerebral artery, internal carotid artery, posterior communicating artery, and posterior cerebral arteries. The circle and its branches supply blood to important areas of the brain, such as the corpus striatum, internal capsule, diencephalon, and midbrain.

The vertebral arteries enter the cranial cavity through the foramen magnum and lie in the subarachnoid space. They then ascend on the anterior surface of the medulla oblongata and unite to form the basilar artery at the base of the pons. The basilar artery has several branches, including the anterior inferior cerebellar artery, labyrinthine artery, pontine arteries, superior cerebellar artery, and posterior cerebral artery.

The internal carotid arteries also have several branches, such as the posterior communicating artery, anterior cerebral artery, middle cerebral artery, and anterior choroid artery. These arteries supply blood to different parts of the brain, including the frontal, temporal, and parietal lobes. Overall, the Circle of Willis and its branches play a crucial role in providing oxygen and nutrients to the brain.

As a result of the volume overload caused by heart failure, she will have a higher susceptibility to chest infections due to pulmonary edema and leg infections due to peripheral edema.

Chronic heart failure can be managed through drug treatment, according to updated guidelines issued by NICE in 2018. While loop diuretics are useful in managing fluid overload, they do not reduce mortality in the long term. The first-line treatment for all patients is a combination of an ACE-inhibitor and a beta-blocker, with clinical judgement used to determine which one to start first. Aldosterone antagonists are recommended as second-line treatment, but potassium levels should be monitored as both ACE inhibitors and aldosterone antagonists can cause hyperkalaemia. Third-line treatment should be initiated by a specialist and may include ivabradine, sacubitril-valsartan, hydralazine in combination with nitrate, digoxin, and cardiac resynchronisation therapy. Other treatments include annual influenzae and one-off pneumococcal vaccines. Those with asplenia, splenic dysfunction, or chronic kidney disease may require a booster every 5 years.